menu
    • menu
    [{"orgOrder":0,"company":"Chroma Dermatology","sponsor":"DermBiont","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Ruboxistaurin","moa":"Protein kinase C beta","graph1":"Dermatology","graph2":"Phase I","graph3":"Chroma Dermatology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chroma Dermatology \/ DermBiont","highestDevelopmentStatusID":"6","companyTruncated":"Chroma Dermatology \/ DermBiont"}]

    Find Clinical Drug Pipeline Developments & Deals by Chroma Dermatology

    Menu

    Chroma Dermatology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chroma Dermatology

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Chroma Dermatology

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ruboxistaurin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : DermBiont

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            DermBiont Raises $28 Million and Acquires Chromaderm to Expand Targeted Topical Therapeutics in Development

                            Details : Acquisition of clinical-stage biotechnology company Chromaderm by DermBiont, will accelerate the development of Chromaderm’s drug candidate, ruboxistaurin (SM-030), topical formulation of the first and only targeted drug to treat skin hyperpigmentation...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 21, 2021

                            Lead Product(s) : Ruboxistaurin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : DermBiont

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth